Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|November 8, 2013
Drug Development: What is a CRO?
Mitchell Katz, PhD, executive director, medical research operations at Purdue Pharma L.P., explains the function of a Contract Research Organization (CRO) and its role in drug development.
Advertisement
Mitchell Katz, PhD, executive director, medical research operations at Purdue Pharma L.P., explains the function of a Contract Research Organization (CRO) and its role in drug development.
This video was shot at the 2013 Drug Information Association (DIA) meeting in Boston, Massachusetts.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5